CoChat
Sign Up
Cited by 470Nitric Oxide and Endothelin EffectsRenin-Angiotensin System StudiesEicosanoids and Hypertension Pharmacology

Nox1 Is Involved in Angiotensin II–Mediated Hypertension: A Study in Nox1-Deficient Mice

Matsuno, Kuniharu, Yamada, Hiroyuki, Iwata, Kazumi, Jin, Denan, Katsuyama, Masato, Matsuki, Masato, Takai, Shinji, Yamanishi, Kiyofumi +3 more·2005·Circulation
DOI 10.1161/circulationaha.105.573709
Open this paper in CoChat — free account

Abstract

Background—Increased production of reactive oxygen species (ROSs) by angiotensin II (Ang II) is involved in the initiation and progression of cardiovascular diseases. NADPH oxidase is a major source of superoxide generated in vascular tissues. Although Nox1 has been identified in vascular smooth muscle cells as a new homolog of gp91phox (Nox2), a catalytic subunit of NADPH oxidase, the pathophysiological function of Nox1-derived ROSs has not been fully elucidated. To clarify the role of Nox1 in Ang II–mediated hypertension, we generated Nox1-deficient (−/Y) mice. Methods and Results—No difference in the baseline blood pressure was observed between Nox1+/Y and Nox1−/Y. Infusion of Ang II induced a significant increase in mean blood pressure, accompanied by augmented expression of Nox1 mRNA and superoxide production in the aorta of Nox1+/Y, whereas the elevation in blood pressure and production of superoxide were significantly blunted in Nox1−/Y. Conversely, the infusion of pressor as well as subpressor doses of Ang II did elicit marked hypertrophy in the thoracic aorta of Nox1−/Y similar to Nox1+/Y. Administration of a nitric oxide synthase inhibitor (L-NAME) to Nox1+/Y did not affect the Ang II–mediated increase in blood pressure, but it abolished the suppressed pressor response to Ang II in Nox1−/Y. Finally, endothelium-dependent relaxation and the level of cGMP in the isolated aorta were preserved in Nox1−/Y infused with Ang II. Conclusions—A pivotal role for ROSs derived from Nox1/NADPH oxidase was suggested in the pressor response to Ang II by reducing the bioavailability of nitric oxide.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.105.573709

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Topiroxostat is a potent inhibitor of XO and induces a covalent modification in the enzyme that inactivates XO after complex dissociation.

    “Topiroxostat is a potent inhibitor of XO and induces a covalent modification in the enzyme that inactivates XO after complex dissociation (629, 703, 821).”

    From Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation (2019) · cites this paper as [629]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Matsuno, K., Yamada, H., Iwata, K., Jin, D., Katsuyama, M., Matsuki, M., Takai, S., Yamanishi, K., Miyazaki, M., Matsubara, H., & Yabe-Nishimura, C.
Affiliations
  • Kyoto Prefectural University of Medicine (JP)
  • From the Department of Pharmacology (K.M., K.I., M.K., C.Y.-N.), Department of Cardiovascular Medicine (H.Y., H.M.), and Department of Dermatology (M. Matsuki, K.Y.), Kyoto Prefectural University of Medicine, Kyoto; and the Department of Pharmacology, Osaka Medical College (D.J., S.T., M. Miyazaki), Osaka, Japan. Drs Matsuki and Yamanishi are now at the Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Japan.
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2005-10-25
Volume
112
Issue
17
Pages
2677-2685
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/circulationaha.105.573709
OpenAlex
W2160571418
Cited by
470
References
30
Citations by year
2026: 7 · 2025: 12 · 2024: 16 · 2023: 18 · 2022: 12 · 2021: 13 · 2020: 11 · 2019: 15 · 2018: 16 · 2017: 25 · 2016: 29 · 2015: 30 · 2014: 32 · 2013: 27 · 2012: 39
FWCI
16.18
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
NOX1, angiotensin II, hypertension, reactive oxygen species, NADPH oxidase, superoxide, nitric oxide bioavailability, pressor response, nitric oxide synthase, cyclic GMP, endothelium-dependent relaxation
MeSH terms
NADPH Oxidase 1, Angiotensin II, Animals, Biological Availability, Blood Pressure, Disease Models, Animal, Heart Rate, Hypertension, Mice, Inbred Strains, Muscle, Smooth, Vascular, NADH, NADPH Oxidoreductases, Nitric Oxide, Reactive Oxygen Species, Mice, Knockout, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review